ProMIS Neurosciences (PMN) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Key milestones and financial position

• Completed enrollment of 144 patients in a robust, placebo-controlled phase 1b Alzheimer's study, exceeding targets.

• Secured up to $175 million in oversubscribed financing from top-tier investors, ensuring funding through upcoming data readouts.

• Interim analysis of trial data expected mid-year, with final top-line results anticipated by year-end.

• Study design enables potential direct transition to pivotal phase 3, bypassing phase 2.

• High patient retention and investigator enthusiasm attributed to promising safety profile.

Scientific approach and platform differentiation

• EpiSelect platform enables design of highly selective antibodies targeting toxic oligomers, not plaque or monomers.

• PMN310 is the only antibody in development shown not to bind plaque, reducing risk of ARIA and off-target effects.

• Platform supports a pipeline targeting misfolded proteins in ALS, Parkinson's, and Lewy body dementia.

• Proof of concept in Alzheimer's would validate the broader platform and pipeline.

• Proprietary approach positions the company as a leader in selective oligomer targeting.

Clinical trial design and endpoints

• Phase 1b trial includes early Alzheimer's patients with mild cognitive impairment, using three ascending doses.

• Endpoints include a comprehensive biomarker panel, safety (especially ARIA), and clinical outcomes (CDR sum of boxes, ADAS-Cog).

• Study is double-blind, placebo-controlled, and designed for definitive efficacy and safety answers.

• Interim analysis will focus on qualitative trends in biomarkers and safety.

• Final unblinded analysis will compare biomarker reductions to benchmarks from other leading therapies.